echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > PD-1 track "fight" fiercely, Hengrui, Cinda, etc. have the upper hand in the "battlefield" of indications

    PD-1 track "fight" fiercely, Hengrui, Cinda, etc. have the upper hand in the "battlefield" of indications

    • Last Update: 2020-09-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On the 12th, Cinda Bio announced that the company and Lilly jointly developed the innovative PD-1 inhibitor Dabershu (Cindili monoanti-injection) combined with kenzo (injection with gisithamin) and platinum chemotherapy for scaly non-small cell lung cancer NSCLC first-line treatment of the new adaptation application was officially accepted by the State Drug Administration.
    Previously, the National Drug Administration has also officially accepted the sDNA of Dabershu (Syndili monoantigen injection) combined libita (injected with pyridoxine di sodium) and platinum for non-scaly NSCLC first-line treatment.
    01 Lung Cancer Field: PD-1 Hot Layout In the PD-1 battle, lung cancer has been the most competitive field.
    cancer is the first malignant tumor with morbidity and mortality in China, and there are huge unsoponsed medical needs.
    of all lung cancers, non-small cell lung cancer (NSCLC) accounted for about 80% to 85%, of which non-scale NSCLC accounted for 70% and scaly NSCLC accounted for 30%.
    lung cancer is expected to account for 40% of the domestic PD-1 market share, estimated market size of 16.829 billion yuan, which is why NSCLC has gradually become the most competitive field of PD-1 antibody adaptive disorders in China.
    the current domestic market PD-1 monoantigen in the field of adaptive diseases have cross, especially in the field of lung cancer.
    In June 2018, BMS PD-1 mono-anti-Opdivo was approved as the first immunotherapy PD-1 monoantigenic drug to be marketed on Chinese mainland as a second-line treatment for advanced metastasis non-small cell lung cancer that drives gene mutation-negative, as a secondary treatment for local late stage or metastasis of chemotherapy. In April
    , Mercadon's PD-1 single-anti-Keytruda combined with Pymetroce and platinum chemotherapy drugs first-line treatment of the mesoplasmic growth factor subjectivity (EGFR) gene mutation negative and mesolytic lymphoma kinase (ALK) negative metastatic non-squamous non-small cell lung cancer adaptation certificate was also officially approved in China, "K drug" became the first PD-1 single resistance for advanced tumor first-line treatment.
    In June this year, Henri Pharmaceutical PD-1 inhibitor Karelli pearl monoantigen anti-combined Pyme segaplatin first-line treatment of advanced or metastatic non-squamous non-small cell lung cancer new adaptive application was officially approved for listing, so that Karelli pearl monoantigen has officially joined the first-line treatment of lung cancer.
    in Therailju monotherapy in Baiji Shenzhou is also focused on the field of lung cancer, with a number of clinical trials on lung cancer conducted simultaneously around the world.
    RATIONALE 304 study on the treatment of first-line advanced non-squamous non-small cell lung cancer for the first-line non-squamous non-small cell lung cancer was also published in April this year, and the application for the listing of the new adaptation has been accepted by NMPA;
    regenerative biology at the 2019 World Lung Cancer Congress announced the results of the company's PD-1 inhibitor Tripri monoantigenated carpentry and Pygmy curvature treatment for EGFR-TKI treatment failure of late stage or recurrence with EGFR sensitive mutation non-small cell lung cancer results.
    results suggest that the treatment is expected to be a new standard treatment option for NSCLC patients after EGFR-TKI treatment failed.
    2020, the pace of the layout of Syndilly monoanti in the field of first-line NSCLC treatment is equally exciting.
    advantage of Xinda Bio's Xindili monoanti-anti-injection is price, compared with the front-runner, "K-Drug."
    In the absence of medicare reimbursements, the cost of the single-drug treatment is about 102,300 yuan (about $14,680) a year, while the annual cost of treatment for "K"is about 286,600 yuan ($41,132), and the cost of the "K-drug" is only one-third.
    As the only PD-1 product currently available for medicare (category B range), in 2019 Syndicated monoantigen reduced its price by 64% for the treatment of recurring/refracticable classic Hodgkin's lymphoma, and Syndicated monoantigen requires fewer patients after Medicare reimbursement.
    analysts believe that, with the acceptance of a number of lung cancer adaptations, if you want to have a place in the domestic PD-1 NSCLC war, the price of the drug may be further reduced to smooth access to the health insurance catalog, which will also bring fast market volume for Xindili single resistance, in the clinical field of lung cancer or will be the leading K drug.
    02 To expand the adaptive domestic PD-1 impact 1 billion threshold at this stage of the domestic market PD-1 single resistance presents a 4 plus 2 competitive pattern.
    according to Frost Sullivan's analysis, China's anti-PD-1/L1 inhibitor market is expected to reach 66.4 billion yuan in 2023 and grow to 98.8 billion yuan in 2030.
    in the huge market temptation, the major enterprises are accelerating the pace of product development, grab market share.
    Li Kang, senior vice president and head of biopharmaceity research and development at Baiji Shenzhou, believes that the expansion of adaptive disorders can bring about an increase in market share, and the number of PD-1 adaptive disorders determines the competitive advantage of the product to a certain extent.
    the future who can expand more adaptive disorders, who has a more reasonable price, who naturally seize market share.
    foreign investment, K medicine is still strong, more than half of the O drug.
    Keytruda topped Top 3 with $11.08 billion in global sales and Opdivo to top 8 with $7.2 billion in Fierce Pharma's 2019 list of the world's top 10 best-selling drugs.
    enter 2020, the advantages of the K drug are even more obvious.
    Keytruda had $6,672 million in first-half revenue, while Opdivo had cumulative revenue of just $3.419 billion.
    , Keytruda and Opdivo were approved for five and three adaptations, respectively, in the country.
    four domestic PD-1s performed differently.
    July, Xindili Mono-Resistance announced the latest sales, in the first half of 2020, Xindili single-resistance cumulative revenue of about 900 million yuan.
    xindili monoanti, although currently approved only one adaptation certificate, but as the only PD-1 inhibitor entering the national health insurance catalog, the price drop of more than 60%, so that it has more protection in sales.
    the financial results of Q1 and Q2 for 2020 previously announced by Baiji Shenzhou, the cumulative revenue for the first half of the first half of the year was US$49.95 million, or about RMB348 million.
    , which went on sale in March this year, has been approved in China for two adaptations, Hodgkin's lymphoma and urethra cancer.
    although it was listed late for Reilly Pearl, it gradually gained the upper hand in the "chasing war" of adaptive disorders.
    as of the time of writing, Junshi Bio has not disclosed its second-quarter results.
    First Quarter sales of $172 million.
    As the first domestic PD-1 product approved in China, the adaptive disorder is an inexorable or metastasis melanoma after the failure of systemic treatment, which will have sales of 774 million yuan in 2019.
    Henrui Pharmaceutical PD-1 inhibitor Karelli pearl monoanti is currently the most approved domestic PD-1 adaptive products.
    is approved in the fields of Hodgkin's lymphoma, liver cancer, esophageal squamous cancer, and non-squamous NSCLC.
    , according to IQVIA data, in the first half of 2020 Karelli Pearl single-resistance sales have exceeded 2 billion yuan.
    the first half of revenue disclosed by each company, PD-1 sales of more than 1 billion yuan in 2020 is not a dream.
    It is worth noting that, in addition to the four pharmaceutical companies listed, the domestic market has a total of 15 anti-PD-1 single-anti-drug drugs in the clinical or listing application stage, the rapid progress of the new drug market application for PD-1 Saipali single-anti-injection has been obtained The State Drug Administration accepted, adaptive for the treatment of second-line recurrence or refractory classic Hodgkin lymphoma patients, Jia and biological PD-1 single anti-Jeno single anti-injection drug market application was also accepted by the State Drug Administration, for the treatment of external T-cell lymphoma.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.